Head of Global Product Quality-Biologics

Trigeminal Neuralgia Pipeline Outlook highlights 10+ Companies and 10+ emerging therapies across clinical development stages. September 29 Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock-like or stabbing pain in a region of the face, most frequently affecting the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left. (Albany, US) September 28, 2026 - DelveInsight's "Trigeminal Neuralgia - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Trigeminal Neuralgia pipeline landscape, covering clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as inactive pipeline products. Geographic Reference Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic, with bilateral trigeminal neuralgia rare and warranting concern about an underlying neurologic or non-neurologic disorder affecting the cranium. Incidence is higher among women than men and increases with age. Key Takeaways from the Trigeminal Neuralgia Pipeline Report * The Trigeminal Neuralgia pipeline includes 10+ key companies developing therapies, with 10+ products spanning Phase III, Phase II, Phase I, preclinical, and discovery stages, along with discontinued and inactive candidates. * Biogen has the most advanced Trigeminal Neuralgia drug candidate in the pipeline, with Vixotrigine (BIIB074) currently in Phase III development. * Vixotrigine is a centrally and peripherally acting small molecule that functions as a voltage- and use-dependent sodium channel blocker, being developed by Biogen for the treatment of Trigeminal Neuralgia. * Rimegepant, developed by Biohaven Pharmaceuticals, is a calcitonin gene-related peptide (CGRP) receptor antagonist in Phase II development for Trigeminal Neuralgia, with a trial initiated in June 2019. * The pipeline includes therapies across multiple stages of development, highlighting continued innovation in neuropathic pain treatment. * Emerging therapies are being developed through diverse mechanisms, including sodium channel blockers and CGRP receptor antagonists. Gain Strategic Insights into the Trigeminal Neuralgia Pipeline Landscape * Explore the complete Trigeminal Neuralgia Pipeline Outlook. * Analyze Phase III, Phase II, Phase I, preclinical, and discovery-stage assets. * Evaluate emerging companies and late-stage pipeline therapies. * Understand therapeutic assessment by product type, route of administration, and molecule type. * Track collaborations, licensing, acquisitions, and other pipeline development activities. Explore detailed pipeline insights and emerging therapies @ Trigeminal Neuralgia Pipeline Insight Report Trigeminal Neuralgia Disease Overview Pain can be triggered by routine acts, including brushing teeth, shaving, touching the face, eating or drinking, speaking, or a breeze on the face. Diagnosis is clinical, based on pain restricted to the territory of one or more divisions of the trigeminal nerve and sudden, intense, very short paroxysms. The anticonvulsant agents carbamazepine and oxcarbazepine have been considered first-choice treatments for control of paroxysmal pain, with gabapentin, pregabalin, and antidepressant agents tried as additional agents. Microvascular decompression is favored as the surgical procedure for cases not responding to medication. Trigeminal Neuralgia Emerging Drugs Analysis The Trigeminal Neuralgia pipeline features multiple emerging therapies targeting neuropathic pain through novel mechanisms and differentiated therapeutic approaches. Phase III Therapy Counseling Services * Vixotrigine (BIIB074): Biogen - A centrally and peripherally acting small molecule voltage- and use-dependent sodium channel blocker. It is currently the most advanced candidate in the Trigeminal Neuralgia pipeline and is being evaluated in Phase III clinical development. Phase II Therapy * Rimegepant: Biohaven Pharmaceuticals - A calcitonin gene-related peptide (CGRP) receptor antagonist currently being evaluated in Phase II development for Trigeminal Neuralgia, with clinical development initiated in June 2019. Further product details on additional pipeline candidates are provided in the full report. Trigeminal Neuralgia Therapeutic Assessment The report provides comprehensive therapeutic assessment of Trigeminal Neuralgia drugs across multiple development and product parameters. Clinical Trial Phases * Late-stage products (Phase III). * Mid-stage products (Phase II). * Early-stage products (Phase I). * Preclinical candidates. * Discovery-stage candidates. * Discontinued and inactive pipeline candidates. Route of Administration * Intravenous. * Subcutaneous. * Oral. * Intramuscular. Molecule Type * Monoclonal antibody. * Small molecule. * Peptide. Product Type * Mono. * Combination. * Mono/Combination. Trigeminal Neuralgia Pipeline Development Landscape The Trigeminal Neuralgia pipeline reflects ongoing innovation across clinical and preclinical development, with multiple companies advancing therapies targeting neuropathic pain through differentiated mechanisms of action. The pipeline spans early discovery through Phase III clinical development and includes both active and inactive candidates, providing insights into the evolving research landscape. Discover Which Companies and Pipeline Therapies Are Advancing Trigeminal Neuralgia Treatment @ Trigeminal Neuralgia Pipeline Insights Counseling Services Scope of the Trigeminal Neuralgia Pipeline Report * Geography Covered: Global. * Coverage: 10+ companies and 10+ pipeline drugs across clinical and nonclinical development stages. * Clinical Stages Covered: Phase III, Phase II, Phase I, preclinical, discovery, inactive, and discontinued products. * Therapeutic Assessment: Product type, clinical stage, route of administration, and molecule type. * Additional Coverage: Collaborations, acquisitions and mergers, licensing, designations, and other product-related development activities. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides actionable market intelligence and strategic insights across the pharmaceutical, biotechnology, and healthcare industries. With expertise in epidemiology forecasting, competitive intelligence, and pipeline analysis, DelveInsight helps organizations make informed business decisions and stay ahead in an evolving healthcare landscape. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Mehul Malhotra Email: Send Email Phone: 09650213330 Address:A-1 NV 89107 City: delhi State: Indiana Country: United States Website: https://www.delveinsight.com/

Basecamp Research raises $140M to advance AI-designed therapeutics. Sep 23, 2026, 09:00 ET * Oversubscribed Series C led by S32 with backing from NVIDIA and others * Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships * The company has demonstrated strong preclinical results across multiple modalities and disease areas LONDON and BOSTON, Sept. 23, 2026 /PRNewswire/ - Basecamp Research, a frontier AI company developing AI-designed medicines, today announced a $140M Series C financing to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics towards clinical development. Basecamp's ambition is to develop cures for diseases that remain incurable by designing medicines that reprogram the body to repair itself. The company combines frontier AI models trained on proprietary biological data with technology for writing DNA sequences into cells. "We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how," said Glen Gowers, co-founder and CEO of Basecamp Research. "AI-based approaches promise to change what's possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most." The oversubscribed round was led by S32, with participation from Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Additional investment comes from senior leaders from across pharma, biotech, and global industry, including André Hoffmann, Vice-Chairman of Roche, who said: "The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey. Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate." Applying EDEN to develop new therapies Basecamp Research is applying EDEN, its biological foundation model, to in vivo cell therapy - reprogramming a patient's cells inside the body. Today's cell therapies are limited both in the complexity of what they can deliver and by a manufacturing process that costs hundreds of thousands of dollars per patient. By pairing EDEN's ability to design long and complex DNA sequences with large serine recombinases that can precisely integrate them into the genome, Basecamp's platform aims to underpin the future of cell therapies, making them more sophisticated, more customisable and simpler to administer. This has the potential to transform how we treat cancer, autoimmune disease, and more. The company has demonstrated strong preclinical results across multiple modalities and disease areas. To expand its pharmaceutical partnerships, Basecamp has appointed Richard Pearce, formerly of Biogen, as Chief Business Officer. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, who joins the Board of Directors, said: "AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people's lives. Basecamp Research is building an important technology platform at the center of that opportunity." The AI and data powering Basecamp Research's therapies At the centre of Basecamp Research's AI platform is the Trillion Gene Atlas, the world's largest proprietary biological AI training dataset. Built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, the Atlas draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents. Trained on this data, the company's EDEN models recognise patterns across a huge breadth of previously unseen biology. Unlike AI systems developed for a single scientific task, EDEN models aim to deliver a universal understanding of how DNA works across all of life. This means that the models can generate potential therapeutic candidates directly from information about a disease, an approach already demonstrated through Basecamp's collaboration with Anthropic on Claude Science. The EDEN models' capabilities include designing cell and gene therapies, enzymes and peptides. About Basecamp Research Basecamp Research trains frontier AI models for therapeutic design. The EDEN models are trained on the Trillion Gene Atlas, the world's largest proprietary genomic dataset, collected through partnerships in more than 30 countries worldwide. Its pipeline of EDEN-designed therapeutics, beginning with in vivo cell therapy, is advancing towards clinical development. Basecamp Research is headquartered in London with offices and labs in Cambridge, MA. SOURCE Basecamp Research

Cambridge, Mass. – May 14, 2026 – Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen.